Volume 2.03 | Jan 24

Pulmonary Cell News 2.03 January 24, 2013
Pulmonary Cell News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Pulmonary Cell News on Twitter
The COX2/PGE2 Pathway Maintains Senescence of Chronic Obstructive Pulmonary Disease Fibroblasts
Researchers report that prostaglandin E2 (PGE2) is a critical component of an amplifying and self-perpetuating circle inducing senescence and inflammation in chronic obstructive pulmonary disease fibroblasts. [Am J Respir Crit Care Med] Abstract

Training Course: Culture Primary Human Bronchial Epithelial Cells at the Air-Liquid Interface
PUBLICATIONS (Ranked by impact factor of the journal)

3D Culture Model to Distinguish Normal from Malignant Human Bronchial Epithelial Cells
Using a reconstituted laminin-rich basement membrane (Matrigel), scientists were able to culture normal human bronchial epithelial cells and a subset of malignant cells. [Eur Respir J] Abstract

Synergy of IL-27 and TNF-α in Regulating CXCL10 Expression in Lung Fibroblasts: Implications in Airway Inflammation
Researchers investigated whether IL-27 modulated the synthesis of CXCL10 in primary human lung fibroblasts (HLF). HLF were activated by IL-27 alone, or in combination with other cytokines. [Am J Resp Cell Mol] Abstract

p62 SQSTM1 /LC3b Complex Confers Cytoprotection on Lung Epithelial Cells after Hyperoxia
Lung alveolar epithelial cells have abundant p62 expression and the p62 level is up-regulated by oxidative stress at both protein and mRNA levels. Researchers found that deletion of the p62 PBI domain or UBA domain both lead to elevated truncated BID, cleaved caspase 3 and significantly more cell death after hyperoxia. [Am J Resp Cell Mol] Abstract

Mitochondrial Electron Transport Is Inhibited by Disappearance of Metallothionein in Human Bronchial Epithelial Cells Following Exposure to Silver Nitrate
Researchers exposed human bronchial epithelial cells (BEAS-2B) to AgNO3 and investigated uptake and intracellular distribution of Ag, expression of metallothionein, generation of reactive oxygen species, and changes in mitochondrial respiration. [Toxicology] Abstract | Graphical Abstract

Toll Like Receptor 4 Is not Targeted to the Lysosome in Cystic Fibrosis Airway Epithelial Cells
Investigators examined the intracellular trafficking of toll-like-receptor 4 in cystic fibrosis (CF) and non-CF airway epithelial cells following stimulation with LPS. Only CF cells displayed persistent expression of Rab7b following stimulation. [Am J Physiol Lung Cell Mol Physiol] Abstract

Genotoxic and Inflammatory Effects of Organic Extracts from Traffic-Related Particulate Matter in Human Lung Epithelial A549 Cells: The Role of Quinones
Researchers found that significant cytotoxicity and DNA damage was caused by organic extracts from traffic-related particulate matter (oTRP). The pro-inflammatory genes, interleukin-6, interleukin-8 and tumor necrosis factor, and two aromatic hydrocarbon receptor-regulated genes, Cyp1a1 and 1b1, were significantly up-regulated by oTRP. [Toxicol In Vitro] Abstract


LKB1 Inactivation Dictates Therapeutic Response of Non-Small Cell Lung Cancer to the Metabolism Drug Phenformin
Scientists report that therapeutic trials in Kras-dependent mouse models of non-small cell lung cancer revealed that tumors with Kras and Lkb1 mutations, but not those with Kras and p53 mutations, showed selective response to phenformin as a single agent, resulting in prolonged survival. [Cancer Cell] Abstract

Methylation of Breast Cancer Susceptibility Gene 1 (BRCA1) Predicts Recurrence in Patients With Curatively Resected Stage I Non-Small Cell Lung Cancer
Using the methylation-specific polymerase chain reaction assay, promoter methylation of the breast cancer susceptibility gene 1 (BRCA1) was assessed in cancer tissues from 70 patients with curatively resected stage I non-small cell lung cancer. The clinical relevance of BRCA1 methylation status was evaluated in terms of outcome of the disease. [Cancer] Abstract

Middle Infrared Radiation Induces G2/M Cell Cycle Arrest in A549 Lung Cancer Cells
The authors developed a middle infrared radiation emitter with emission wavelength band in the 3-5 µm region to irradiate A549 lung adenocarcinoma cells. They found that middle infrared radiation exposure inhibited cell proliferation and induced morphological changes by altering the cellular distribution of cytoskeletal components. [PLoS One] Full Article

RNA interference Targeting Human FAK and EGFR Suppresses Human Non-Small-Cell Lung Cancer Xenograft Growth in Nude Mice
Investigators report that knockdown of focal adhesion kinase (FAK) and epidermal growth factor receptor (EGFR) expression significantly inhibited cell proliferation and induced cell apoptosis of A549 lung cancer cells in vitro. [Cancer Gene Ther] Abstract

PneumaCult™-ALI Medium for Bronchial Epithelial Cells: Watch the Video

ALK Inhibitors: A New Targeted Therapy in the Treatment of Advanced NSCLC
The authors discuss the discovery of anaplastic lymphoma kinase (ALK) rearrangements, the clinical epidemiology of lung cancer driven by ALK, the clinical data for ALK-targeted therapy in non-small cell lung cancer (NSCLC), and ongoing ALK inhibitor-based clinical trials. [Target Oncol] Abstract

U.S. FDA Grants Priority Review to Boehringer Ingelheim’s Afatinib NDA for EGFR Mutation-Positive Advanced NSCLC
Boehringer Ingelheim Pharmaceuticals Inc. announced that the New Drug Application (NDA) for its investigational oncology compound afatinib has been accepted for filing and granted Priority Review by the U.S. Food and Drug Administration (FDA). The application for afatinib is currently under review for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with an epidermal growth factor receptor (EGFR) mutation as detected by an FDA-approved test. [Boehringer Ingelheim Pharmaceuticals Inc.] Press Release

Epic Sciences Awarded a Phase II SBIR Contract from NCI/NIH to Develop a Lung Cancer Diagnostic Blood Test
Epic Sciences, Inc., announced receipt of a Phase II contract from the Small Business Innovation Research (SBIR) program supported by the National Cancer Institute (NCI) and the National Institutes of Health (NIH). The contract will fund the further development of an assay to identify and characterize circulating tumor cells in lung cancer patients. The results of this contract are expected to provide a basis for the development of new cancer diagnostic products. [Epic Sciences, Inc.] Press Release

Celtaxsys Brings Leading Researchers in Respiratory Diseases Together to Serve on Medical Advisory Panel
Celtaxsys, Inc., announced the appointments of Edward E. Philpot, M.D, J. Stuart Elborn, M.D., Richard B. Moss, M.D., Steven M. Rowe, M.D., M.S.P.H., and Michael S. Schechter, M.D., M.P.H., to its new Medical Advisory Panel. [Celtaxsys, Inc.] Press Release


National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)


5th International Meeting on Pulmonary Rare Diseases and Orphan Drugs
February 8-9, 2013
Milan, Italy

our events page to see a complete list of events in the pulmonary cell community.


Scientist or Engineer – hPSC Bioengineer (STEMCELL Technologies, Inc)

Postdoctoral Fellows – Gene, RNA and Epigenetic Regulation, Protein Science, Signal Transduction, Cell and Stem Cell, Cancer and Other Diseases (Shanghai Institute of Biochemistry and Cell Biology)

Postdoctoral Position – Host-Pathogen Interaction at Mucosal Surfaces (Sanford Burnham Medical Research Institute)

Postdoctoral Fellow – Mouse Genetics/Cancer Genomics (Fred Hutchinson Cancer Research Center)

Postdoctoral Fellowship – Translational Studies of Interstitial Lung Disease (University of California San Francisco)

Postdoctoral/ Research Associate/ Senior Research Associate – Lung Alveolar Epithelial Cell Biology (University of Southern California)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Pulmonary Cell News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.

Learn more about Pulmonary Cell News: Archives | Events | Contact Us